BECTON, DICKINSON AND COMPANY Becton, Dickinson and Company Share Price BOERSE MUENCHEN
Equities
BOX
US0758871091
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 217.5 EUR | +1.12% |
|
-2.33% | -1.36% |
| Sales 2024 * | 20.25B 18.9B 1,602B | Sales 2025 * | 21.42B 20B 1,694B | Capitalization | 67.54B 63.06B 5,342B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.09B 1.95B 166B | Net income 2025 * | 2.48B 2.31B 196B | EV / Sales 2024 * | 3.98 x |
| Net Debt 2024 * | 13.13B 12.26B 1,039B | Net Debt 2025 * | 10.8B 10.08B 854B | EV / Sales 2025 * | 3.66 x |
| P/E ratio 2024 * |
32.8
x | P/E ratio 2025 * |
29.1
x | Employees | - |
| Yield 2024 * |
1.61% | Yield 2025 * |
1.64% | Free-Float | 77.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on Becton, Dickinson and Company
More recommendations
More press releases
| 1 week | -2.33% | ||
| Current month | +1.97% | ||
| 1 month | +4.37% | ||
| 3 months | -5.23% | ||
| 6 months | -1.36% | ||
| Current year | -1.36% |
1 week
213.60
223.90
1 month
205.00225.60
3 years
198.00264.30
5 years
182.17264.30
10 years
83.64264.30
| Managers | Title | Age | Since |
|---|---|---|---|
Thomas Polen
CEO | Chief Executive Officer | 50 | 31/12/08 |
| Director of Finance/CFO | 52 | 05/09/21 | |
| Chief Tech/Sci/R&D Officer | 48 | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bertram Scott
BRD | Director/Board Member | 73 | 23/09/02 |
Catherine Burzik
BRD | Director/Board Member | 73 | 28/01/13 |
| Director/Board Member | 69 | 25/07/10 |
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 217.5 | +1.12% |
| 27/06/24 | 215.1 | -0.69% |
| 26/06/24 | 216.6 | -1.10% |
| 25/06/24 | 219 | -0.50% |
| 24/06/24 | 220.1 | -1.17% |
Real-time BOERSE MUENCHEN, June 28, 2024 at 08:43 pm
More quotes
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Calendar
31/07/2024
- Q3 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
233.7
USD
Average target price
279.2
USD
Spread / Average Target
+19.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.60% | 181B | |
| -4.45% | 101B | |
| -8.63% | 45.09B | |
| +9.70% | 44.37B | |
| +6.13% | 40.7B | |
| +15.22% | 29.85B | |
| +14.80% | 24.49B | |
| -6.46% | 23.99B | |
| -10.82% | 22.33B |
- Stock Market
- Equities
- BDX Stock
- BOX Stock
